PHVS · Pharvaris N.V.

This 6-K discloses a material equity financing event: Pharvaris N.V. has entered into an underwriting agreement to sell 3,874,664 ordinary shares, with a potential additional 581,199 shares via the over-allotment option. The offering is conducted under an effective Form F-3 shelf registration (File No. 333-278650), confirming SEC qualification and enabling timely execution. As a Dutch public company (naamloze vennootschap), Pharvaris is issuing newly authorized shares with a nominal value of €0.12 — a procedural detail reflecting Dutch corporate law but not altering economic rights. The absence of disclosed pricing, gross proceeds, or use of proceeds limits assessment of financial impact; however, the scale of the offering (nearly 4.5 million shares) signals a significant capital raise likely intended to fund clinical development, regulatory activities, or general corporate purposes typical for a biopharmaceutical company. The involvement of Morgan Stanley and Leerink — both specialized in life sciences — reinforces the strategic importance of this financing. Importantly, the legal opinion from NautaDutilh confirms the validity, full payment, and non-assessable nature of the shares upon issuance, mitigating near-term legal risk around share issuance. For investors, this represents concrete dilution and a vote of confidence in the Company’s capital strategy, though without pricing or use-of-proceeds details, the precise strategic intent and valuation implications remain unspecified in this filing.